Companies / DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc.

Nasdaq: DMACCIK 1401040MINNEAPOLIS, MN

Financials

Revenue
Net income$-32.77M
Total debt
Cash$5.13M
Diluted EPS
Shares outstanding53.9M

Ownership

53.9M shares outstanding · as of Aug 3, 2026
1.0%Insiders
Ownership
Insiders1.01%544,499
Institutions23.71%12,784,019
Public float75.28%40,597,179

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 9

View all →
Insider% of sharesShares
0.74%398,587
0.18%97,949
0.09%47,963
Kellen ScottCFO & Secretary
Krop JulieChief Medical Officer
Lewis TanyaDirector
Pauls Dietrich JohnCEOPresident & CEO · Director

Institutional holders 98

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q2 2026
as of
BlackRock, Inc.
13F manager
AddCommon Stock$2.47M+351K
+18.49%
2,252,285
4.18% of shares
low
Q1 2026
as of
Millennium Management LLC
13F manager
AddCommon Stock$1.13M+167K
+21.73%
935,592
1.73% of shares
low
Q4 2025
as of
Cantor Fitzgerald, L. P.
13F manager
ExitCommon Stock$-687.0K-100K
-100.00%
0
low
Q1 2026
as of
Renaissance Technologies LLC
13F manager
NewCommon Stock$355.6K+53K
52,523
0.10% of shares
low
Q1 2026
as of
Marshall Wace, LLP
13F manager
ExitCommon Stock$-256.3K-32K
-100.00%
0
low
Q2 2026
as of
LPL Financial LLC
13F manager
AddCommon Stock$255.9K+36K
+18.44%
233,500
0.43% of shares
low
Q1 2026
as of
Royal Bank of Canada
13F manager
TrimCommon Stock$-225.6K-34K
-58.97%
23,343
0.04% of shares
low
Q2 2026
as of
Quadrature Capital Ltd
13F manager
ExitCommon Stock$-187.6K-24K
-100.00%
0
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Trill ABPassive13G/A
Dialectic Life Sciences SPV LLCPassive13G/A
Cooperman Leon GPassive13G/A

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
DMACCommon StockEquity25253X207BBG000LP4YD7